Innovation1 Biotech Inc.
IVBTOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4494
P/E Ratio—
52W High$0.0002
52W Low$0.0002
Innovation1 Biotech Inc. (IVBT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IVBT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2023Report Date: May 31, 2023EPS Actual
-$0.01
Revenue
—
Fiscal Period
Q2 FY2023
FY ends December
Report Date
May 31, 2023
After Market Close
IVBT reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2023 | May 31, 2023 | — | -$0.01 | — | — | — | — |
| — Q1 FY2023 | Feb 28, 2023 | — | -$0.01 | — | — | — | — |
| — Q4 FY2022 | Nov 30, 2022 | — | -$0.05 | — | — | — | — |
| — Q3 FY2022 | Aug 31, 2022 | — | -$0.04 | — | — | — | — |
| — Q2 FY2022 | May 31, 2022 | — | -$0.12 | — | — | — | — |
| — Q1 FY2022 | Feb 28, 2022 | — | -$0.13 | — | — | — | — |
| — Q4 FY2021 | Nov 30, 2021 | — | -$0.04 | — | — | — | — |
| — Q3 FY2021 | Aug 31, 2021 | — | -$0.01 | — | — | — | — |
Q2 FY2023
May 31, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Feb 28, 2023
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 30, 2022
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 31, 2022
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
May 31, 2022
EPS Actual
-$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2022
Feb 28, 2022
EPS Actual
-$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Nov 30, 2021
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2021
Aug 31, 2021
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2023 | May 31, 2023 | — | $0.18 | $0.18 | +0.00% |
| — Q1 FY2023 | Feb 28, 2023 | — | $0.27 | $0.27 | +0.00% |
| — Q4 FY2022 | Nov 30, 2022 | — | $0.10 | $0.10 | +0.00% |
| — Q3 FY2022 | Aug 31, 2022 | — | $0.15 | $0.15 | +0.00% |
| — Q2 FY2022 | May 31, 2022 | — | $0.46 | $0.46 | +0.00% |
| — Q1 FY2022 | Feb 28, 2022 | — | $1.02 | $1.02 | +0.00% |
| — Q4 FY2021 | Nov 30, 2021 | — | $3.56 | $3.05 | -14.33% |
| — Q3 FY2021 | Aug 31, 2021 | — | $2.00 | $3.00 | +50.00% |
Q2 FY2023+0.00%
Report Date
May 31, 2023
EPS Beat/Miss
—
Price Before
$0.18
Price After
$0.18
Q1 FY2023+0.00%
Report Date
Feb 28, 2023
EPS Beat/Miss
—
Price Before
$0.27
Price After
$0.27
Q4 FY2022+0.00%
Report Date
Nov 30, 2022
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q3 FY2022+0.00%
Report Date
Aug 31, 2022
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.15
Q2 FY2022+0.00%
Report Date
May 31, 2022
EPS Beat/Miss
—
Price Before
$0.46
Price After
$0.46
Q1 FY2022+0.00%
Report Date
Feb 28, 2022
EPS Beat/Miss
—
Price Before
$1.02
Price After
$1.02
Q4 FY2021-14.33%
Report Date
Nov 30, 2021
EPS Beat/Miss
—
Price Before
$3.56
Price After
$3.05
Q3 FY2021+50.00%
Report Date
Aug 31, 2021
EPS Beat/Miss
—
Price Before
$2.00
Price After
$3.00
Beat Rate0 / 8 quarters
Largest Move+50.00% (Q3 FY2021)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IVBT ends December
Innovation1 Biotech Inc. (IVBT) most recently reported earnings on May 31, 2023 for Q2 FY2023, posting EPS of $-0.01 (in line with the analyst consensus of —). The next IVBT earnings date is expected around September 1, 2026.
Each quarter, investors track IVBT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IVBT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IVBT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IVBT earnings · 4 questionsInnovation1 Biotech Inc.'s next earnings report is expected around September 1, 2026. IVBT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IVBT historically reports after market close (AMC).
IVBT earnings datewhen is IVBT earningsIVBT next earnings datewhen does IVBT report earningsIVBT earnings calendar
▸ Source: FMP · Innovation1 Biotech Inc. SEC filings · US GAAP · Innovation1 Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026